insights_auto
Why is AMLX up 3.46%?
Dive Deeperchevron_right
AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$28.14
arrow_upward
+3.46%(+0.94) 1D
$28.14
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMLX...
Open
$27.32
High
$28.60
Low
$26.94
Mkt. cap
3.53B
Avg. vol.
1.55M
Volume
1.47M
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.43
Beta
-0.10
Shares outstanding
125.51M
No. of employees
136
Open
$27.32
High
$28.60
Low
$26.94
Mkt. cap
3.53B
Avg. vol.
1.55M
Volume
1.47M
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.43
Beta
-0.10
Shares outstanding
125.51M
No. of employees
136
News stories
From web sources and news partners
Simply Wall Street
·
2 days ago
Amylyx Pharmaceuticals (AMLX) Could Be 35% Undervalued On Phase 3 LUCIDITY Data Reveal
https://www.dars.gov.et/
·
1 month ago
Amylyx Shares Surge to Record High as Avexitide Advances Toward Commercial Launch - Earnings Risk Report
Barron's
·
1 month ago
Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc